Hyperlipidemia: Are the PCSK9 inhibitors bouncing back?
This article, published by Pharma Times May 2019, considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs.
The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products in multiple markets. These obstacles partly reflect initial premium pricing of the two available PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab). Price differentials have been all the more marked given the established reliability of low-cost, genericised statins as a tool for lowering cholesterol. In that light, many physicians, thought leaders and payers opted to wait for persuasive outcomes data that would substantiate the ability of the PCSK9 inhibitors to offset higher costs with long-term gains in preventing mortality, hospitalisation or other serious cardiovascular events.